Gilead Sciences, Inc. (GILD) Given Hold Rating at Maxim Group
Several other brokerages have also recently issued reports on GILD. Needham & Company LLC reiterated a hold rating on shares of Gilead Sciences in a research note on Monday, August 28th. Vetr upgraded Gilead Sciences from a hold rating to a buy rating and set a $89.27 price objective on the stock in a research note on Wednesday, September 6th. Morgan Stanley reiterated an equal weight rating and issued a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. ValuEngine cut Gilead Sciences from a strong-buy rating to a buy rating in a research note on Wednesday, September 13th. Finally, Bank of America Corporation reduced their price objective on Gilead Sciences from $87.00 to $86.00 and set a neutral rating on the stock in a research note on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $85.64.
Gilead Sciences (NASDAQ GILD) traded down 0.47% on Thursday, reaching $81.21. The company’s stock had a trading volume of 9,187,565 shares. The company has a 50 day moving average of $82.70 and a 200 day moving average of $72.55. The firm has a market capitalization of $106.05 billion, a price-to-earnings ratio of 8.82 and a beta of 1.14. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period last year, the firm earned $3.08 earnings per share. On average, analysts forecast that Gilead Sciences will post $8.74 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Given Hold Rating at Maxim Group” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/gilead-sciences-inc-gild-given-hold-rating-at-maxim-group/1644329.html.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were given a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. Gilead Sciences’s payout ratio is 22.58%.
In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 446,819 shares of company stock valued at $36,338,919. Insiders own 1.30% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Seizert Capital Partners LLC increased its stake in shares of Gilead Sciences by 4.6% during the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after purchasing an additional 27,547 shares in the last quarter. Linscomb & Williams Inc. increased its stake in shares of Gilead Sciences by 3.0% during the 1st quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 154 shares in the last quarter. Investment Centers of America Inc. increased its stake in shares of Gilead Sciences by 7.2% during the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after purchasing an additional 1,958 shares in the last quarter. HealthInvest Partners AB increased its stake in shares of Gilead Sciences by 3.5% during the 1st quarter. HealthInvest Partners AB now owns 117,000 shares of the biopharmaceutical company’s stock worth $7,947,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Capital Asset Advisory Services LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $875,000. 73.97% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.